Long-Term Visual Outcome in Wet Age-Related Macular Degeneration Patients Depending on the Number of Ranibizumab Injections
Purpose. To analyse the visual outcome in wet age-related macular degeneration (AMD) patients depending on the number of ranibizumab injections. Methods. 51 naïve wet AMD patients were retrospectively recorded. Visual acuity (VA), central retinal thickness (CRT) measured with spectral domain (SD) op...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2015-01-01
|
| Series: | Journal of Ophthalmology |
| Online Access: | http://dx.doi.org/10.1155/2015/820605 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850164144626466816 |
|---|---|
| author | Pilar Calvo Beatriz Abadia Antonio Ferreras Oscar Ruiz-Moreno Jesús Leciñena Clemencia Torrón |
| author_facet | Pilar Calvo Beatriz Abadia Antonio Ferreras Oscar Ruiz-Moreno Jesús Leciñena Clemencia Torrón |
| author_sort | Pilar Calvo |
| collection | DOAJ |
| description | Purpose. To analyse the visual outcome in wet age-related macular degeneration (AMD) patients depending on the number of ranibizumab injections. Methods. 51 naïve wet AMD patients were retrospectively recorded. Visual acuity (VA), central retinal thickness (CRT) measured with spectral domain (SD) optical coherence tomography (OCT), and number of intravitreal injections were compared at 6, 12, 18, 24, 30, and 36 months of follow-up. Kaplan-Meier survival rates (SRs) based on VA outcomes were calculated depending on the number of ranibizumab injections performed. Results. VA improved compared with baseline at 6 and 12 months (P<0.005). No differences were found at 18, 24, 30, and 36 months (P>0.05). CRT measured with Cirrus OCT decreased (P<0.001) at all time points analysed. The mean number of injections received was 6.98±3.69. At 36 months, Kaplan-Meier SR was 76.5% (the proportion of patients without a decrease in vision of more than 0.3 logMAR units). VA remained stable (≤0.01 logMAR units) or improved in 62.7%. Within this group, SR was 92.9% in those who received 7 or more injections versus 51.4% receiving <7 treatments (P=0.008; log-rank test). Conclusion. Better VA outcomes were found in stable wet AMD patients after 3 years of follow-up if they received ≥7 ranibizumab injections. |
| format | Article |
| id | doaj-art-eff6a2af0a774074a7d736f2bb66db3b |
| institution | OA Journals |
| issn | 2090-004X 2090-0058 |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Ophthalmology |
| spelling | doaj-art-eff6a2af0a774074a7d736f2bb66db3b2025-08-20T02:22:03ZengWileyJournal of Ophthalmology2090-004X2090-00582015-01-01201510.1155/2015/820605820605Long-Term Visual Outcome in Wet Age-Related Macular Degeneration Patients Depending on the Number of Ranibizumab InjectionsPilar Calvo0Beatriz Abadia1Antonio Ferreras2Oscar Ruiz-Moreno3Jesús Leciñena4Clemencia Torrón5Ophthalmology Department, Miguel Servet University Hospital, Isabel la Catolica 1-3, 50009 Zaragoza, SpainOphthalmology Department, Miguel Servet University Hospital, Isabel la Catolica 1-3, 50009 Zaragoza, SpainOphthalmology Department, Miguel Servet University Hospital, Isabel la Catolica 1-3, 50009 Zaragoza, SpainOphthalmology Department, Miguel Servet University Hospital, Isabel la Catolica 1-3, 50009 Zaragoza, SpainOphthalmology Department, Miguel Servet University Hospital, Isabel la Catolica 1-3, 50009 Zaragoza, SpainOphthalmology Department, Miguel Servet University Hospital, Isabel la Catolica 1-3, 50009 Zaragoza, SpainPurpose. To analyse the visual outcome in wet age-related macular degeneration (AMD) patients depending on the number of ranibizumab injections. Methods. 51 naïve wet AMD patients were retrospectively recorded. Visual acuity (VA), central retinal thickness (CRT) measured with spectral domain (SD) optical coherence tomography (OCT), and number of intravitreal injections were compared at 6, 12, 18, 24, 30, and 36 months of follow-up. Kaplan-Meier survival rates (SRs) based on VA outcomes were calculated depending on the number of ranibizumab injections performed. Results. VA improved compared with baseline at 6 and 12 months (P<0.005). No differences were found at 18, 24, 30, and 36 months (P>0.05). CRT measured with Cirrus OCT decreased (P<0.001) at all time points analysed. The mean number of injections received was 6.98±3.69. At 36 months, Kaplan-Meier SR was 76.5% (the proportion of patients without a decrease in vision of more than 0.3 logMAR units). VA remained stable (≤0.01 logMAR units) or improved in 62.7%. Within this group, SR was 92.9% in those who received 7 or more injections versus 51.4% receiving <7 treatments (P=0.008; log-rank test). Conclusion. Better VA outcomes were found in stable wet AMD patients after 3 years of follow-up if they received ≥7 ranibizumab injections.http://dx.doi.org/10.1155/2015/820605 |
| spellingShingle | Pilar Calvo Beatriz Abadia Antonio Ferreras Oscar Ruiz-Moreno Jesús Leciñena Clemencia Torrón Long-Term Visual Outcome in Wet Age-Related Macular Degeneration Patients Depending on the Number of Ranibizumab Injections Journal of Ophthalmology |
| title | Long-Term Visual Outcome in Wet Age-Related Macular Degeneration Patients Depending on the Number of Ranibizumab Injections |
| title_full | Long-Term Visual Outcome in Wet Age-Related Macular Degeneration Patients Depending on the Number of Ranibizumab Injections |
| title_fullStr | Long-Term Visual Outcome in Wet Age-Related Macular Degeneration Patients Depending on the Number of Ranibizumab Injections |
| title_full_unstemmed | Long-Term Visual Outcome in Wet Age-Related Macular Degeneration Patients Depending on the Number of Ranibizumab Injections |
| title_short | Long-Term Visual Outcome in Wet Age-Related Macular Degeneration Patients Depending on the Number of Ranibizumab Injections |
| title_sort | long term visual outcome in wet age related macular degeneration patients depending on the number of ranibizumab injections |
| url | http://dx.doi.org/10.1155/2015/820605 |
| work_keys_str_mv | AT pilarcalvo longtermvisualoutcomeinwetagerelatedmaculardegenerationpatientsdependingonthenumberofranibizumabinjections AT beatrizabadia longtermvisualoutcomeinwetagerelatedmaculardegenerationpatientsdependingonthenumberofranibizumabinjections AT antonioferreras longtermvisualoutcomeinwetagerelatedmaculardegenerationpatientsdependingonthenumberofranibizumabinjections AT oscarruizmoreno longtermvisualoutcomeinwetagerelatedmaculardegenerationpatientsdependingonthenumberofranibizumabinjections AT jesuslecinena longtermvisualoutcomeinwetagerelatedmaculardegenerationpatientsdependingonthenumberofranibizumabinjections AT clemenciatorron longtermvisualoutcomeinwetagerelatedmaculardegenerationpatientsdependingonthenumberofranibizumabinjections |